Why carry out this study?
|
There are limited data on ivabradine therapy in black patients and none in African Americans. |
The aim of the current study was to assess the effect of ivabradine on heart rate (HR) and physical activity when added to guideline-directed therapy in African American patients with heart failure with reduced ejection fraction (HFrEF). |
What was learned from the study?
|
Ivabradine 2.5–7.5 mg twice daily demonstrated effective HR reduction from baseline in African American patients with HFrEF. |
These data support ivabradine use in African American patients with HFrEF who meet typical treatment criteria. |
Introduction
Methods
Study Design and Patients
Endpoints
Statistical Analysis
Compliance with Ethics Guidelines
Results
Characteristic | Ivabradine (N = 30) |
---|---|
Sex, n (%) | |
Male | 21 (70.0) |
Female | 9 (30.0) |
Age (years) | |
Mean (SD) | 55.7 (12.6) |
18–64 years, n (%) | 24 (80.0) |
≥ 65 years, n (%) | 6 (20.0) |
Systolic blood pressure (mmHg), mean (SD) | 126.8 (17.1) |
Diastolic blood pressure (mmHg), mean (SD) | 73.0 (5.7) |
Heart rate (beats per minute), mean (SD) | 83.6 (8.9) |
B-type natriuretic peptide, median (Q1, Q3) | 136 (48, 325) |
NYHA class, n (%) | |
Class II | 22 (73.3) |
Class III | 8 (26.7) |
Primary cause of heart failure, n (%) | |
Ischemic heart disease | 5 (16.7) |
Non-ischemic heart disease | 25 (83.3) |
LVEF (%), mean (SD) | 25.6 (6.8) |